New pill aims to tame severe gut disease
NCT ID NCT07650942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental tablet called Hemay005 in 360 Chinese adults with moderate to severe ulcerative colitis, a chronic gut condition. Participants will receive either the drug or a placebo to see if it can bring about remission and improve symptoms over 12 weeks, with a follow-up phase up to 40 weeks. The goal is to control the disease, not cure it, as ongoing management is typically needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital,Sun Yat-Sen University
Guangzhou, China
-
The Sixth Affiliated Hospital,Sun Yat-Sen University
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Can a new pill tame ulcerative colitis Flare-Ups?
- Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out
- Can a new pill tame ulcerative colitis when others fail?
- Can a pill tame ulcerative colitis? new trial seeks answers